Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for XmAb942 in Inflammatory bowel disease. The expected timing is based on the latest available company guidance and may change.
10/10/24 Present preclinical data at UEG Week. 11/4/24 Doses first subject. 2/27/25- SAD data in H1 2025 & MAD data in H2 2025. 4/29/25- Positive Ph1 interim results; initiate Ph2b in moderate-to-severely active UC (XENITH-UC) in H2 2025 11/05/25:- First patient dosed in Ph2b XENITH-UC ulcerative colitis study; enrollment ongoing. 01/08/26:- Final Ph1 healthy volunteer results expected H1 2026; XENITH-UC Ph2b progress update near year-end 2026. 02/26/26:- Final Ph1 healthy volunteer results at DDW May 2-5 2026; XENITH-UC Ph2b update around year-end 2026. 05/04/26:- Final Ph1 results at DDW. XENITH-UC interim analysis expected Year-End 2026; primary endpoint analysis H2 2027. 05/06/26:- Final Ph1 DDW results showed well-tolerated dosing, favorable immunogenicity, ~74-day half-life; XENITH-UC interim YE26, primary H2 2027. 08/05/26:- XENITH-UC interim remains around YE 2026; primary endpoint expected in H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.